A2A at Biopharma

Updated: Feb 7, 2020

A2A participated at the AI Applications Summit Biopharma discussing the urgency to advance AI applications in industry to bring benefits to patients faster

May 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st...

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...